cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Aligos Therapeutics Inc
3 own
11 watching
Current Price
$1.75
$-0.17
(-8.85%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
74.93M
52-Week High
52-Week High
3.17
52-Week Low
52-Week Low
0.8401
Average Volume
Average Volume
0.18M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization74.93M
icon52-Week High3.17
icon52-Week Low0.8401
iconAverage Volume0.18M
iconDividend Yield--
iconP/E Ratio--
What does the Aligos Therapeutics Inc do?
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Read More
How much money does Aligos Therapeutics Inc make?
News & Events about Aligos Therapeutics Inc.
Globe Newswire
30days ago
Final cohort of Phase 1 study projected to be complete in H1 2023 Phase 2-enabling GLP toxicology studies projected to be complete in H2 2023 Clinical update on all pipeline programs to be presented at the 2023 J.P. Morgan Healthcare Conference on January 12 at 10:30 a.m. PT SOUTH SAN FRANCISCO, ...
Globe Newswire
1month ago
Coronavirus protease inhibitor, ALG-097558, has demonstrated antiviral activity in vivo and promising pan-coronavirus activity in vitroFirst-in-human studies anticipated to begin in H1 2023 SOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a ...
Globe Newswire
3 months ago
ALG-055009, aTHR-agonist drug candidate in development as a treatment for NASH, demonstrated dose-dependent reductions in several atherogenic lipids and a favorable pharmacokinetic profile in subjects with hyperlipidemia Aligos oral and poster presentations also collectively highlight new data from ...
Globe Newswire
3 months ago
Reductions in hepatitis B surface antigen levels observed in a subset of subjects with chronic hepatitis B enrolled in Phase 1 study ALG-000184-201SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company ...
Globe Newswire
3 months ago
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced seven upcoming poster presentations...
Frequently Asked Questions
Frequently Asked Questions
What is Aligos Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Aligos Therapeutics Inc shares?
plus_minus_icon
How can I buy Aligos Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Aligos Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Aligos Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Aligos Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Aligos Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Aligos Therapeutics Inc?
plus_minus_icon
What percentage is Aligos Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Aligos Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.75
$-0.17
(-8.85%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
ONCTERNAL THERAPEUTICS INC
ONCTERNAL THERAPEUTICS INC
$1.09
$-0.03 (-2.68 %)
IMMUNIC INC
IMMUNIC INC
$2.87
$0.30 (11.67 %)
Seelos Therapeutics Inc
Seelos Therapeutics Inc
$0.84
$-0.03 (-2.96 %)
Passage Bio Inc
Passage Bio Inc
$1.55
$-0.01 (-0.64 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
ONCTERNAL THERAPEUTICS INC
ONCTERNAL THERAPEUTICS INC
$1.09
$-0.03 (-2.68 %)
IMMUNIC INC
IMMUNIC INC
$2.87
$0.30 (11.67 %)
Seelos Therapeutics Inc
Seelos Therapeutics Inc
$0.84
$-0.03 (-2.96 %)
Passage Bio Inc
Passage Bio Inc
$1.55
$-0.01 (-0.64 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00